

Administration, 10903 New Hampshire Ave., Bldg. 32, Rm. 5154, Silver Spring, MD 20993, 240-402-3838, email: marieann.brill@fda.hhs.gov, or FDA Advisory Committee Information Line, 1-800-741-8138 (301-443-0572 in the Washington, DC area). A notice in the **Federal Register** about last minute modifications that impact a previously announced advisory committee meeting cannot always be published quickly enough to provide timely notice. Therefore, you should always check the Agency's website at <https://www.fda.gov/AdvisoryCommittees/default.htm> and scroll down to the appropriate advisory committee meeting link, or call the advisory committee information line to learn about possible modifications before coming to the meeting.

SUPPLEMENTARY INFORMATION:

Agenda: On Friday, May 11, 2018, the PAC and EMDAC will meet to discuss drug development for the treatment of children with achondroplasia. The following topics should be considered for discussion: Evidence required to establish dose-response, study design, study duration, intended population, and endpoints. In the open session, the committee does not intend to discuss any individual research programs.

FDA intends to make background material available to the public no later than 2 business days before the meeting. If FDA is unable to post the background material on its website prior to the meeting, the background material will be made publicly available at the location of the advisory committee meeting, and the background material will be posted on FDA's website after the meeting. Background material is available at <https://www.fda.gov/AdvisoryCommittees/Calendar/default.htm>. Scroll down to the appropriate advisory committee meeting link.

Procedure: On May 11, 2018, from 12 p.m. to 6 p.m., the meeting is open to the public. Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Written submissions may be made to the contact person on or before May 4, 2018. Oral presentations from the public will be scheduled between approximately 1 p.m. and 2:30 p.m. Those individuals interested in making formal oral presentations should notify the contact person and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time requested to make

their presentation on or before May 4, 2018. Time allotted for each presentation may be limited. If the number of registrants requesting to speak is greater than can be reasonably accommodated during the scheduled open public hearing session, FDA may conduct a lottery to determine the speakers for the scheduled open public hearing session. The contact person will notify interested persons regarding their request to speak by May 7, 2018.

Closed Committee Deliberations: On May 11, 2018, from 8 a.m. to 11 a.m., the meeting will be closed to permit discussion and review of trade secret and/or confidential commercial information (5 U.S.C. 552b(c)(4)). During this session, the committees will discuss the premarketing drug development program of an investigational product.

Persons attending FDA's advisory committee meetings are advised that FDA is not responsible for providing access to electrical outlets.

FDA welcomes the attendance of the public at its advisory committee meetings and will make every effort to accommodate persons with disabilities. If you require accommodations due to a disability, please contact Marieann Brill (see **FOR FURTHER INFORMATION CONTACT**) at least 7 days in advance of the meeting.

FDA is committed to the orderly conduct of its advisory committee meetings. Please visit our website at <https://www.fda.gov/AdvisoryCommittees/AboutAdvisoryCommittees/ucm111462.htm> for procedures on public conduct during advisory committee meetings.

Notice of this meeting is given under the Federal Advisory Committee Act (5 U.S.C. app. 2).

Dated: April 20, 2018.

Leslie Kux,

Associate Commissioner for Policy.

[FR Doc. 2018-08766 Filed 4-25-18; 8:45 am]

BILLING CODE 4164-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Health Resources and Services Administration

National Vaccine Injury Compensation Program; List of Petitions Received

AGENCY: Health Resources and Services Administration (HRSA), Department of Health and Human Services (HHS).

ACTION: Notice.

SUMMARY: HRSA is publishing this notice of petitions received under the

National Vaccine Injury Compensation Program (the program), as required by the Public Health Service (PHS) Act, as amended. While the Secretary of HHS is named as the respondent in all proceedings brought by the filing of petitions for compensation under the program, the United States Court of Federal Claims is charged by statute with responsibility for considering and acting upon the petitions.

FOR FURTHER INFORMATION CONTACT: For information about requirements for filing petitions and the program in general, contact Lisa L. Reyes, Clerk of Court, United States Court of Federal Claims, 717 Madison Place NW, Washington, DC 20005, (202) 357-6400. For information on HRSA's role in the Program, contact the Director, National Vaccine Injury Compensation Program, 5600 Fishers Lane, Room 08N146B, Rockville, MD 20857; (301) 443-6593, or visit our website at: <http://www.hrsa.gov/vaccinecompensation/index.html>.

SUPPLEMENTARY INFORMATION: The program provides a system of no-fault compensation for certain individuals who have been injured by specified childhood vaccines. Subtitle 2 of Title XXI of the PHS Act, 42 U.S.C. 300aa-10 *et seq.*, provides that those seeking compensation are to file a petition with the United States Court of Federal Claims and to serve a copy of the petition on the Secretary of HHS, who is named as the respondent in each proceeding. The Secretary has delegated this responsibility under the program to HRSA. The Court is directed by statute to appoint special masters who take evidence, conduct hearings as appropriate, and make initial decisions as to eligibility for, and amount of, compensation.

A petition may be filed with respect to injuries, disabilities, illnesses, conditions, and deaths resulting from vaccines described in the Vaccine Injury Table (the table) set forth at 42 CFR 100.3. This table lists for each covered childhood vaccine the conditions that may lead to compensation and, for each condition, the time period for occurrence of the first symptom or manifestation of onset or of significant aggravation after vaccine administration. Compensation may also be awarded for conditions not listed in the Table and for conditions that are manifested outside the time periods specified in the table, but only if the petitioner shows that the condition was caused by one of the listed vaccines.

Section 2112(b)(2) of the PHS Act, 42 U.S.C. 300aa-12(b)(2), requires that "[w]ithin 30 days after the Secretary

receives service of any petition filed under section 2111 the Secretary shall publish notice of such petition in the **Federal Register**.” Set forth below is a list of petitions received by HRSA on March 1, 2018, through March 31, 2018. This list provides the name of petitioner, city and state of vaccination (if unknown then city and state of person or attorney filing claim), and case number. In cases where the Court has redacted the name of a petitioner and/or the case number, the list reflects such redaction.

Section 2112(b)(2) also provides that the special master “shall afford all interested persons an opportunity to submit relevant, written information” relating to the following:

1. The existence of evidence “that there is not a preponderance of the evidence that the illness, disability, injury, condition, or death described in the petition is due to factors unrelated to the administration of the vaccine described in the petition,” and

2. Any allegation in a petition that the petitioner either:

a. “[S]ustained, or had significantly aggravated, any illness, disability, injury, or condition not set forth in the Vaccine Injury Table but which was caused by” one of the vaccines referred to in the Table, or

b. “[S]ustained, or had significantly aggravated, any illness, disability, injury, or condition set forth in the Vaccine Injury Table the first symptom or manifestation of the onset or significant aggravation of which did not occur within the time period set forth in the Table but which was caused by a vaccine” referred to in the table.

In accordance with Section 2112(b)(2), all interested persons may submit written information relevant to the issues described above in the case of the petitions listed below. Any person choosing to do so should file an original and three (3) copies of the information with the Clerk of the United States Court of Federal Claims at the address listed above (under the heading **FOR FURTHER INFORMATION CONTACT**), with a copy to HRSA addressed to Director, Division of Injury Compensation Programs, Healthcare Systems Bureau, 5600 Fishers Lane, 08N146B, Rockville, MD 20857. The Court’s caption (Petitioner’s Name v. Secretary of HHS) and the docket number assigned to the petition should be used as the caption for the written submission. Chapter 35 of title 44, United States Code, related to paperwork reduction, does not apply to information required for purposes of carrying out the program.

Dated: April 20, 2018.

George Sigounas,
Administrator.

List of Petitions Filed

1. Gerald Kiel, Farmington Hills, Michigan, Court of Federal Claims No: 18–0314V
2. Jill Silver, Brighton, Michigan, Court of Federal Claims No: 18–0315V
3. Mark Kelner, Salisbury, North Carolina, Court of Federal Claims No: 18–0316V
4. Amy Morris, Drumright, Oklahoma, Court of Federal Claims No: 18–0317V
5. Marcie Unrue, Crown Point, Indiana, Court of Federal Claims No: 18–0323V
6. Lesa Myers, Philadelphia, Pennsylvania, Court of Federal Claims No: 18–0324V
7. Janie Miller, Upper Arlington, Ohio, Court of Federal Claims No: 18–0327V
8. Matthew Rhodes, Alexandria, Virginia, Court of Federal Claims No: 18–0329V
9. Debra L. Bevel on behalf of Michael S. Bevel, Tulsa, Oklahoma, Court of Federal Claims No: 18–0331V
10. Derek Clark, Lakewood, Ohio, Court of Federal Claims No: 18–0332V
11. John Morgan, Phoenix, Arizona, Court of Federal Claims No: 18–0336V
12. Ronni Cook, Chambersburg, Pennsylvania, Court of Federal Claims No: 18–0337V
13. Kim Duguay, Lewiston, Maine, Court of Federal Claims No: 18–0340V
14. Kathleen Gullo, Scotts Valley, Arizona, Court of Federal Claims No: 18–0350V
15. Tamara Kuypers, Burlington, Vermont, Court of Federal Claims No: 18–0351V
16. Clayton T. Coleman, Novi, Michigan, Court of Federal Claims No: 18–0352V
17. Brianna Rich and Jeffrey Rich on behalf of S.G.R., Albuquerque, New Mexico, Court of Federal Claims No: 18–0353V
18. Cheryl Doster-Anderson, Orlando, Florida, Court of Federal Claims No: 18–0354V
19. Desirea Tyler, Fort Wayne, Indiana, Court of Federal Claims No: 18–0355V
20. Alicea Armstrong on behalf of Kenneth Armstrong, Deceased, Baltimore, Maryland, Court of Federal Claims No: 18–0356V
21. Youhong Lu, Santa Clara, California, Court of Federal Claims No: 18–0358V

22. Michael Bull, Kansas City, Kansas, Court of Federal Claims No: 18–0361V
23. Steven Fletcher, Boston, Massachusetts, Court of Federal Claims No: 18–0362V
24. Laura Johnson, Grand Rapids, Michigan, Court of Federal Claims No: 18–0363V
25. Karen Cain, Madill, Oklahoma, Court of Federal Claims No: 18–0364V
26. Elmia Walker, Carteret, New Jersey, Court of Federal Claims No: 18–0366V
27. Yeshi Fesaha Mengistu, North Bend, Washington, Court of Federal Claims No: 18–0368V
28. Karen Booth on behalf of J.B., Towson, Maryland, Court of Federal Claims No: 18–0372V
29. Kari Smith, Junction City, Oregon, Court of Federal Claims No: 18–0374V
30. Christa Jean Bingham, Des Moines, Washington, Court of Federal Claims No: 18–0376V
31. Jayne Purdom, El Dorado Springs, Missouri, Court of Federal Claims No: 18–0377V
32. Clemey Robinson, Chicago, Illinois, Court of Federal Claims No: 18–0378V
33. Robert Folino, Saugus, Massachusetts, Court of Federal Claims No: 18–0380V
34. Julia Wells, Deltona, Florida, Court of Federal Claims No: 18–0381V
35. Clifton E. Carlton, Sr., Mankato, Minnesota, Court of Federal Claims No: 18–0384V
36. Patricia Garcia, Phoenix, Arizona, Court of Federal Claims No: 18–0385V
37. William Morrison, Sarasota, Florida, Court of Federal Claims No: 18–0386V
38. Ronnie A Newcomer, Clarksville, Tennessee, Court of Federal Claims No: 18–0388V
39. Gerald Gordon, Phoenix, Arizona, Court of Federal Claims No: 18–0390V
40. Beverly Blad, Penn Yan, New York, Court of Federal Claims No: 18–0391V
41. Irene Russano, Waldwick, New Jersey, Court of Federal Claims No: 18–0392V
42. Jay LaMont, Logan, Utah, Court of Federal Claims No: 18–0394V
43. Sabrina Chappell-Strickland, Morrisville, North Carolina, Court of Federal Claims No: 18–0396V
44. Raymond Markarian, Santa Clarita, California, Court of Federal Claims No: 18–0397V
45. Nancy Brock, Sicklerville, New Jersey, Court of Federal Claims No: 18–0399V

46. Argelio Garcia, North Bend, Washington, Court of Federal Claims No: 18-0401V
47. Jo Ann Gilbert, Pennsville, New Jersey, Court of Federal Claims No: 18-0402V
48. Travis Eason, Montgomery, Alabama, Court of Federal Claims No: 18-0406V
49. Sean Kaplan, Chicago, Illinois, Court of Federal Claims No: 18-0407V
50. Amarachi Grace Otuokere, Austin, Texas, Court of Federal Claims No: 18-0409V
51. Shelle Johnson, Chatfield, Minnesota, Court of Federal Claims No: 18-0410V
52. Amber Etheridge, Tuscaloosa, Alabama, Court of Federal Claims No: 18-0411V
53. Mary E. Lyons, Seattle, Washington, Court of Federal Claims No: 18-0414V
54. Christian Park, Dothan, Alabama, Court of Federal Claims No: 18-0415V
55. Jennifer Talbot, South Weymouth, Massachusetts, Court of Federal Claims No: 18-0416V
56. Joy Houston, New Orleans, Louisiana, Court of Federal Claims No: 18-0420V
57. Kristian M. Ellingsen, Sterling, Virginia, Court of Federal Claims No: 18-0421V
58. Harry D. Tanner, Jr., Monroe, North Carolina, Court of Federal Claims No: 18-0422V
59. Philip Arcadipane, Brockton, Massachusetts, Court of Federal Claims No: 18-0423V
60. Keith McCarville, Newton, Iowa, Court of Federal Claims No: 18-0424V
61. Sharon Rons, Sioux Falls, South Dakota, Court of Federal Claims No: 18-0425V
62. Mary George, Boston, Massachusetts, Court of Federal Claims No: 18-0426V
63. Sandra Posh-Denzler, Stratford, Connecticut, Court of Federal Claims No: 18-0427V
64. Richard Chester, Minocqua, Wisconsin, Court of Federal Claims No: 18-0428V
65. Rebekah Morgan, Henderson, Nevada, Court of Federal Claims No: 18-0429V
66. Ruby Katherine Gordon on behalf of C.C., Kings Mountain, North Carolina, Court of Federal Claims No: 18-0431V
67. Dawn Eberhardt, Madison, Wisconsin, Court of Federal Claims No: 18-0432V
68. Rufus D. Parker, Shelby, North Carolina, Court of Federal Claims No: 18-0434V
69. Miranda Sellers, Washington, District of Columbia, Court of Federal Claims No: 18-0435V
70. John Bayles, Washington, District of Columbia, Court of Federal Claims No: 18-0436V
71. Louie Garcia, Washington, District of Columbia, Court of Federal Claims No: 18-0438V
72. Gail Linville, Washington, District of Columbia, Court of Federal Claims No: 18-0439V
73. A L V and M V on behalf of AA—VV, Park Ridge, Illinois, Court of Federal Claims No: 18-0440V
74. Tiffany Dagen, Middletown, Pennsylvania, Court of Federal Claims No: 18-0442V
75. Sharon Gregory, Durham, North Carolina, Court of Federal Claims No: 18-0444V
76. Denise Bigda, Boston, Massachusetts, Court of Federal Claims No: 18-0445V
77. Virginia Wilt, Norristown, Pennsylvania, Court of Federal Claims No: 18-0446V
78. Spencer Vick, Fayetteville, Georgia, Court of Federal Claims No: 18-0447V
79. Kevin Randall, Haddonfield, New Jersey, Court of Federal Claims No: 18-0448V
80. Karen Owens, Gainesville, Florida, Court of Federal Claims No: 18-0449V
81. Noah E. Musick, Greensboro, North Carolina, Court of Federal Claims No: 18-0451V
82. Zina Sanders, Tampa, Florida, Court of Federal Claims No: 18-0452V
83. Linda D. Kooker, Erie, Pennsylvania, Court of Federal Claims No: 18-0453V
84. Vincent Ricciardi, Deer Park, New York, Court of Federal Claims No: 18-0455V
85. Raine Learn, Corning, New York, Court of Federal Claims No: 18-0456V
86. Laura Russell, Dresher, Pennsylvania, Court of Federal Claims No: 18-0457V
87. Jodi Mickelson, Clarion, Iowa, Court of Federal Claims No: 18-0459V
88. Chelsea Engel on behalf of A.E., Dresher, Pennsylvania, Court of Federal Claims No: 18-0461V
89. Leonard E Smith, Greensboro, North Carolina, Court of Federal Claims No: 18-0462V
90. Charla Thornton, Washington, District of Columbia, Court of Federal Claims No: 18-0464V
91. Patricia Kelley, Washington, District of Columbia, Court of Federal Claims No: 18-0466V
92. Richard Proctor, Washington, District of Columbia, Court of Federal Claims No: 18-0468V
93. Barbara Plowman, Knoxville, Tennessee, Court of Federal Claims No: 18-0469V
94. Kelly Dean, Lancaster, Ohio, Court of Federal Claims No: 18-0470V
95. Rita Czyzewski, Berlin, New Jersey, Court of Federal Claims No: 18-0471V
96. Philip Yeakel, Washington, District of Columbia, Court of Federal Claims No: 18-0472V
97. Benjamin Taylor, Dresher, Pennsylvania, Court of Federal Claims No: 18-0473V

[FR Doc. 2018-08715 Filed 4-25-18; 8:45 am]

BILLING CODE 4165-15-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Establishment of the National Clinical Care Commission and Solicitation of Nominations for Commission Members

AGENCY: Office of Disease Prevention and Health Promotion, Office of the Assistant Secretary for Health, Office of the Secretary, U.S. Department of Health and Human Services.

ACTION: Notice.

SUMMARY: The U.S. Department of Health and Human Services (HHS) hereby announces the establishment of the National Clinical Care Commission (the Commission) pursuant to the National Clinical Care Commission Act. The Commission will consist of representatives of specific federal agencies and non-federal individuals and entities who represent diverse disciplines and views. The Commission will evaluate and make recommendations to the HHS Secretary and Congress regarding improvements to the coordination and leveraging of federal programs related to awareness and clinical care for complex metabolic or autoimmune diseases that result from issues related to insulin that represent a significant disease burden in the United States, which may include complications due to such diseases.

Through this notice, HHS is also requesting nominations of individuals who are interested in being considered for appointment to the Commission. Resumes or curricula vitae from qualified individuals who wish to be considered for appointment as a member of the Commission are currently being accepted.

DATES: Nominations must be received no later than close of business May 29, 2018.

ADDRESSES: Qualified persons and interested organizations are invited to